Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Influenza

Free Subscription Articles published in Drug Saf Retrieve available abstracts of 42 articles: HTML format

Single Articles

May 2026
1. HWANG CS, Lu Z, Russo M, Zakoul H, et al
   Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
   Drug Saf. 2026;49:519-528.
   PubMed     Abstract available
   
   
   
2. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
   Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
   Drug Saf. 2026;49:567-580.
   PubMed     Abstract available
   
   
   
3. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
   Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
   Drug Saf. 2026;49:581-590.
   PubMed     Abstract available
   
   
   
4. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
   GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
   Drug Saf. 2026;49:529-539.
   PubMed     Abstract available
   
   
   March 2026
5. MORGAN HJ, Bloomfield L, Clothier HJ, Ngeh S, et al
   Statistical Methods for Multi-jurisdictional Australian Vaccine Safety Investigations of Rare Adverse Events.
   Drug Saf. 2026;49:353-365.
   PubMed     Abstract available
   
   
   January 2026
6. PALMER M, Seekins D, Avigan M, Marcinak J, et al
   The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.
   Drug Saf. 2026;49:9-25.
   PubMed     Abstract available
   
   
   December 2025
7. WONG J, Donegan K, Harrison K, Jan T, et al
   Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective.
   Drug Saf. 2025;48:1365-1385.
   PubMed     Abstract available
   
   
   
8. VAN HOLLE L
   Observed Versus Expected Analysis-How Does It Fit in the Pharmacovigilance Toolkit?
   Drug Saf. 2025;48:1325-1330.
   PubMed     Abstract available
   
   
   October 2025
9. ORDONEZ-MENA JM, Kar D, Fan X, Ferreira F, et al
   Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.
   Drug Saf. 2025;48:1161-1175.
   PubMed     Abstract available
   
   
   August 2025
10. SANKAR C, Evans S, Meyer JC, Gunter HM, et al
    Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System.
    Drug Saf. 2025;48:909-922.
    PubMed     Abstract available
    
    
    July 2025
11. ABATE A, Poncato E, Barbieri MA, Powell G, et al
    Off-the-Shelf Large Language Models for Causality Assessment of Individual Case Safety Reports: A Proof-of-Concept with COVID-19 Vaccines.
    Drug Saf. 2025;48:805-820.
    PubMed     Abstract available
    
    
    June 2025
12. ROQUE-PEREIRA L, Sisay MM, Ogar CK, Duran CE, et al
    Comparison of Adverse Events in Pregnant Persons Receiving COVID-19 and Influenza Vaccines: A Disproportionality Analysis Using Combined Data from US VAERS and EudraVigilance Spontaneous Report Databases.
    Drug Saf. 2025 Jun 10. doi: 10.1007/s40264-025-01561.
    PubMed     Abstract available
    
    
    May 2025
13. HAMZAOUI H, Shaum A, Cherkaoui I, Moussa LA, et al
    Assessment of Pharmacovigilance Across University Hospitals in Morocco.
    Drug Saf. 2025;48:527-539.
    PubMed     Abstract available
    
    
    March 2025
14. NAMBASA VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, et al
    Empowering African Expertise: Enhancing Safety Data Integration and Signal Detection for COVID-19 Vaccines Through the African Union Smart Safety Surveillance Joint Signal Management Group.
    Drug Saf. 2025;48:233-249.
    PubMed     Abstract available
    
    
    
15. BOULEFAA D, Bagheri H, Salvo F, Rabier MB, et al
    Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Drug Saf. 2025;48:251-263.
    PubMed     Abstract available
    
    
    November 2024
16. MORCIANO C, Massari M, Cutillo M, Belleudi V, et al
    Acute Appendicitis After COVID-19 Vaccines in Italy: A Self-Controlled Case Series Study.
    Drug Saf. 2024;47:1157-1169.
    PubMed     Abstract available
    
    
    October 2024
17. CIAPPONI A, Berrueta M, Argento FJ, Ballivian J, et al
    Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
    Drug Saf. 2024;47:991-1010.
    PubMed     Abstract available
    
    
    
18. YAN VKC, Yang Y, Wan EYF, Lai FTT, et al
    Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.
    Drug Saf. 2024;47:1025-1037.
    PubMed     Abstract available
    
    
    
19. BELLITTO C, Luxi N, Ciccimarra F, L'Abbate L, et al
    What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
    Drug Saf. 2024;47:1011-1023.
    PubMed     Abstract available
    
    
    September 2024
20. WYSZYNSKI DF, Demetriou L, Renz C, Aliabadi S, et al
    Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.
    Drug Saf. 2024;47:843-851.
    PubMed     Abstract available
    
    
    August 2024
21. GORDILLO-MARANON M, Szmigiel A, Yalmanova V, Caplanusi I, et al
    COVID-19 Vaccines and Heavy Menstrual Bleeding: The Impact of Media Attention on Reporting to EudraVigilance.
    Drug Saf. 2024;47:783-798.
    PubMed     Abstract available
    
    
    July 2024
22. GORDILLO-MARANON M, Candore G, Hedenmalm K, Browne K, et al
    Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.
    Drug Saf. 2024;47:607-615.
    PubMed     Abstract available
    
    
    June 2024
23. DE LA CUEVA IS, Gerber JE, Hastie A, Brotons C, et al
    Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    Drug Saf. 2024 Jun 29. doi: 10.1007/s40264-024-01456.
    PubMed     Abstract available
    
    
    May 2024
24. CAPLANUSI I, Szmigiel A, van der Elst M, Schougaard Christiansen ML, et al
    The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally.
    Drug Saf. 2024;47:405-418.
    PubMed     Abstract available
    
    
    March 2024
25. DOS SANTOS G, Devadiga R, Kim CS, Bang J, et al
    An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014-2022) Following the Introduction of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged
    Drug Saf. 2024 Mar 14. doi: 10.1007/s40264-024-01395.
    PubMed     Abstract available
    
    
    
26. WYSZYNSKI DF, Papageorghiou AT, Renz C, Metz TD, et al
    The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations.
    Drug Saf. 2024;47:195-204.
    PubMed     Abstract available
    
    
    February 2024
27. MORO PL, Ennulat C, Brown H, Woody G, et al
    Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
    Drug Saf. 2024 Feb 27. doi: 10.1007/s40264-024-01406.
    PubMed     Abstract available
    
    
    
28. QIN SX, Cheng FWT, Kwok WC, Fung LWY, et al
    Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study.
    Drug Saf. 2024;47:135-146.
    PubMed     Abstract available
    
    
    
29. DONG G, Bate A, Haguinet F, Westman G, et al
    Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Drug Saf. 2024;47:173-182.
    PubMed     Abstract available
    
    
    December 2023
30. DE GERMAY S, Singier A, Salvo F, Pariente A, et al
    Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    Drug Saf. 2023;46:1381-1389.
    PubMed     Abstract available
    
    
    November 2023
31. MICALLEF B, Dogne JM, Sultana J, Straus SMJM, et al
    An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance.
    Drug Saf. 2023;46:1089-1103.
    PubMed     Abstract available
    
    
    October 2023
32. SLINGERLAND P, van Hunsel FPAM, Lieber T, van Balveren L, et al
    The Effect of Sex on the Incidence, Latency, Duration and Perceived Burden of Adverse Events Following Seasonal Influenza Vaccination in the Netherlands.
    Drug Saf. 2023 Oct 26. doi: 10.1007/s40264-023-01356.
    PubMed     Abstract available
    
    
    September 2023
33. WALTON M, Pletzer V, Teunissen T, Lumley T, et al
    Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Drug Saf. 2023;46:867-879.
    PubMed     Abstract available
    
    
    June 2023
34. KAUR U, Fatima Z, Maheshwari K, Sahni V, et al
    Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
    Drug Saf. 2023;46:553-563.
    PubMed     Abstract available
    
    
    
35. AHMADIZAR F, Luxi N, Raethke M, Schmikli S, et al
    Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials.
    Drug Saf. 2023;46:575-585.
    PubMed     Abstract available
    
    
    May 2023
36. KRALOVA K, Wilson CA, Richebourg N, D'souza J, et al
    Quality of MedDRA((R)) Coding in a Sample of COVID-19 Vaccine Medication Error Data.
    Drug Saf. 2023;46:501-507.
    PubMed     Abstract available
    
    
    April 2023
37. BAUCHAU V, Davis K, Frise S, Jouquelet-Royer C, et al
    Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
    Drug Saf. 2023;46:327-333.
    PubMed     Abstract available
    
    
    
38. RAETHKE M, van Hunsel F, Thurin NH, Dureau-Pournin C, et al
    Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose.
    Drug Saf. 2023;46:391-404.
    PubMed     Abstract available
    
    
    
39. OGAR CK, Quick J, Gilbert HN, Vreman RA, et al
    Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Drug Saf. 2023;46:357-370.
    PubMed     Abstract available
    
    
    March 2023
40. KALKNER KM, Sundstrom A, Nurminen ML, Larsson M, et al
    Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.
    Drug Saf. 2023;46:319-321.
    PubMed    
    
    
    
41. WYSZYNSKI DF, Bhattacharya M, Martinez-Perez O, Scialli AR, et al
    The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations.
    Drug Saf. 2023;46:297-308.
    PubMed     Abstract available
    
    
    
42. ZAPATA-CACHAFEIRO M, Prieto-Campo A, Portela-Romero M, Carracedo-Martinez E, et al
    Effect of Previous Anticoagulant Treatment on Risk of COVID-19.
    Drug Saf. 2023;46:273-281.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum